Name	Shruti Chaturvedi, MBBS, MSCI
Current Position & Affiliation	Associate Professor of Medicine, Director of Research, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore MD
Country	United States
Major Field	Hematology

Educational Background

2010	M.B.B.S., University of Delhi (Maulana Azad Medical College), New Delhi, India
2017	Master of Science in Clinical Investigation (MSCI), Vanderbilt University, Nashville, TN
2011-2014	Resident, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
2014-2017	Fellowship, Hematology and Oncology, Vanderbilt University, Nashville, TN

Professional Experience

2017-present	Attending Physician, Johns Hopkins Hospital
2024- Present	Research Director, Division of Hematology, Johns Hopkins University School of Medicine

Other Experience and Professional Memberships

2011-Present	American College of Physicians
2012-present	American Society of Hematology
2012-Present	Hemostasis and Thrombosis Research Society
2013-Present	International Society on Thrombosis and Hemostasis
2014-Present	American Society of Clinical Oncology
2021-2023	National Kidney Foundation, Working Group: Atypical hemolytic uremic syndrome: Recommendations for revising the nomenclature (Group co-chair)
2021-2024	Communications Committee, Hemostasis and Thrombosis Research Society
2021-2025	Committee on Educational Affairs, American Society of Hematology
2021-2025	CME Accreditation Committee, American Society of Hematology
2023-2025	Vice Chair, HTRS Publications Committee
2021-Present	Director, United States Thrombotic Microangiopathy Consortium
2024-present	Board of Directors, Hemostasis and Thrombosis Research Society
2022-Present	Council of early career researchers in thrombosis (CERT), a committee of the National Blood Clot Alliance

Main Scientific Publications

1. **Chaturvedi S**, Carcioppollo D, Zhang L, and McCrae KR. Management and Outcomes for Patients with TTP: Analysis of 100 Cases at a Single Institution. Am J Hematol 2013; 88(7):560-565.
2. **Chaturvedi S,** Sidana S, Elson P, Khorana A, McCrae KR. Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One. 2014 Aug 15;9(8):e94048.
3. **Chaturvedi S,** McCrae KR. Over-testing for Heparin-Induced Thrombocytopenia in Hospitalized Patients. J Thromb Thrombolysis. 2014;40(1):12-16.
4. **Chaturvedi S**, Cockrell E, Espinola R, Hsi L, Fulton S, Li, L, Fonseca F, Kundu S, McCrae KR. Circulating Microparticles in patients with antiphospholipid antibodies: Characterization and Associations. Thromb Res. 2015;135(1):102-8.
5. **Chaturvedi S**, Abbas H, McCrae KR. Increased Morbidity During Long Term Follow Up of

Survivors of Thrombotic Thrombocytopenic Purpura. Am J Hematol 2015;91(10)E208.
6. **Chaturvedi S**, Ghafuri DL, Kassim AA, Glassberg J, Rodeghier M, DeBaun MR. Rapidly progressive acute chest syndrome in sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol 2016; 91(12):1185-90.
7. **Chaturvedi S**, Ghafuri DL, Kassim AA, Rodegheir M, DeBaun MR. Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease. Am J Hematol 2017;92(2):125-30.
8. Ghafuri J, **Chaturvedi S**, Kassim AA, Rodegheir M, DeBaun MR. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Ped Blood Cancer 2017;64(7).
9. **Chaturvedi S,** Oluwole O, Cataland S, McCrae KR. Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thrombosis Research 2017;151:51-56.
10. **Chaturvedi S,** Clancy M, Schaefer N, Oluwole O, McCrae KR. Post-traumatic stress disorder and depression in adults with hereditary hemorrhagic telangiectasia. Thrombosis Research 2017;153:14-18.
11. **Chaturvedi S**, Bhatnagar P, Ofori-Acquah S, Williams S, Bean CJ, Steinberg M, Casella J, Casella E, Arking DE, DeBaun MR. Genome wide association study indentifies variants associated with vaso-occlusive pain children with sickle cell anemia. Blood 2017;130(5):686-88.
12. Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Elondou S, Baines AC, **Chaturvedi S**, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement. JCI Insight 2018;3(6).pii:99128
13. **Chaturvedi S,** Clancy M, Schaefer N, Kasthuri RS. Characteristics and outcomes of venous thromboembolism in patients with hereditary hemorrhagic telangiectasia. Thrombosis Research 2018;169:41-43.
14. **Chaturvedi S**, Ghafuri DL, Jordan N, Kassim AA, Rodeghier M, DeBaun MR. Clustering of multiple organ disease and earlier mortality in adults with sickle cell disease: a retrospective-prospective cohort study. Am J Hematol 2018;93(9):1153-1160.
15. DeBaun MR, Ghafuri DL, Rodeghier M, Maitra P, **Chaturvedi S**, Kassim AA, Ataga KI. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood 2019;133(6):615-617.
16. **Chaturvedi S**, Koo M, Dackiw E, Koo G, Frank S, Resar LM. Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. Am J Hematol 2019;94(2):E55-58.
17. Kohli R, Shingina A, New S, **Chaturvedi S**, Benson A, Biggins SW, Bhambha K. Thromboelastography parameters are associated with cirrhosis severity. Digestive Disease and Sciences 2019;64(9):2661-2670.
18. Upreti H, Kasmani J, Dane K, Braunstein EM, Strieff, MB, Moliterno AR, Shanbhag S, Sperati CJ, Kickler TS, Gottesman RF, Brodsky RA, **Chaturvedi** S. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood 2019;134(13):1037-1045.
19. Carlson DS, Bartholomew JR, Gomes MP, McCrae KR, **Chaturvedi S**. Outcomes of cardiovascular surgery utilizing heparin versus direct thrombin inhibitors in patients with previously diagnosed HIT. Thromb Haemost 2019. doi: 10.1055/s-0039-3401825. [Epub ahead of print]
20. **Chaturvedi S**, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, Petri M, Crowther M, McCrae KR, Brodsky, RA. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020;134(24):2125-2126.
21. Karantanos T**, Chaturvedi S,** Braunstein EM, Spivak J, Resar L, Karanika S, Williams DM, Rogers O, Gocke CD, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in mutational burden. Blood Advances 2020;4(12):2567-2576.
22. Liu A, Dhaliwal N, Upreti H, Kasmani J, Dane K, Moliterno M, Streiff MB, Braunstein EM, Brodsky RA, **Chaturvedi S.** Reduced sensitivity of PLASMIC and French Scores for the diagnosis of Thrombotic Thrombocytopenic Purpura (TTP) in Older Individuals. Transfusion 2020 [Online ahead of print].
23. Yu J, Yuan C, Chen H, **Chaturvedi S**, Braunstein B, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood

2020;136(18):2080-2089.

24. **Chaturvedi S**, Hussain S, Upreti H, Dhaliwal N, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome: outcomes and lessons from a physician-directed protocol. Blood Advances 2021;5(5):1504-1512.
25. Sukumar S, Brodsky MA**,** Hussain S, Yanek LR, Moliterno AM, Brodsky RA, Cataland SR**, Chaturvedi S.** Cardiovascular disease is a leading cause of mortality among iTTP survivors in clinical remission. Blood Advances 2021 (doi: 10.1182/bloodadvances.2020004169. Online ahead of print).
26. Brodsky M, Selvakumar S, Hussain S, Moliterno M, Streiff MB, Braunstein EM, Brodsky RA, **Chaturvedi S.** Major Adverse Cardiovascular Outcomes after recovery from Thrombotic Thrombocytopenic Purpura. Am J Hematology 2021 (doi: 10.1002/ajh.26341. Online ahead of print)
27. Braunstein EM, Chen H, Juarez F, Yang F, Tao L, Makhlin I, Williams DM, **Chaturvedi S**, Pallavajjala A, Karantanos T, Martin R, Wohler E, Sobreira N, Gocke CD, Moliterno AR. Germline *ERBB2/HER2* Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers (Basel) 2021;13(13):3246.
28. Yu J, Gerber GF, Chen H, Yuan X, **Chaturvedi S**, Braunstein EM, Brodsky RA. Complement Dysregulation is Associated with Severe COVID-19 Illness. Haematologica 2021 [Accepted, In Press].
29. Gerber GF, Yuan X, Yu J, Cher BAY, Braunstein EM, **Chaturvedi S**, Brodsky RA.COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood 2021 Jul 1;137(26):3670-3673.
30. Gerber FG, SeZern AE, Chaturvedi S, Brodsky RA. A 15-year single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinura patients on terminal complement inhibition with history of thromboembolism. Am J Hematol 2022; 97(2):E59-E62.
31. Shah H, Kim A, Sukumar S, Mazepa MA, Kohli R, Braunstein EM, Brodsky RA, Cataland SR, Chaturvedi S. SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura. Blood 2022;139(16):2570-2573.
32. Kasthuri RS, **Chaturvedi S**, Thomas S, Vandergrift N, Bann C, Schaefer SN, Clancy MS, Pyeritz R, McCrae KR. Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument. Blood Adv 2022;6(14):4301-4309.
33. **Chaturvedi S**, Antun AG, Farland AM, Woods R, Metjian AD, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreiziger L, Sadler EJ, Sridharan M, Go RS, McCrae KR, Upreti H, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Camias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA for the United States Thrombotic Microangiopathy Consortium. Race, Rituximab and Relapse in TTP. Blood 2022;140(12):1335-1344.
34. Shah H, Chen H, Pan XZ, Metjian AD, Brodsky RA, Braunstein EM, **Chaturvedi S**. C5 inhibition allows continued antineoplastic therapy in cancer and chemotherapy-associated thrombotic microangiopathy. Blood Adv 2022 (Online ahead of print)
35. Brown J, Potugari B, Mazepa MA, Kohli R, Moliterno AR, Brodsky RA, Vaught JA, Burwick R, **Chaturvedi S.** Maternal and fetal outcomes of pregnancy after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura. Ann Hematol 2022 (Online ahead of print)
36. Frank SM, Pippa A, Sherd I, Scott AV, Lo BD, Cruz NC, Hendricks EA, Ness PM, **Chaturvedi S**, Resar LMS. Methods of Bloodless Care, Clinical Outcomes, and Costs for Adult Patients Who Decline Allogeneic Transfusions. Anesth Analg 2022;135(3):576-585.
37. Karantanos T, Kaizer H, **Chaturvedi S**, Resar LM, Moliterno AM. Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. EClinical medicine 2020;21:100324.
38. Agbani EO, Mahe E, **Chaturvedi S**, Yamamura L, Schneider P, Barber MRW, Choi M, Lee A, Skeith L. Platelets and neutrophils co=drive procoagulant potential in secondary antiphospholipid syndrome during pregnancy. Thromb Res 2022;220:141-144.
39. Cruz NC, Guinn NR, Adegboye J, Hsiao J, Thomas AJ, Lo BD, Chaturvedi S, Resar LMS, Frank SM. A novel algorithm to calculate target preoperative hemoglobin for patients declining allogeneic transfusion. J Clin Anesth. 2023 Feb 27;87:111070.
40. **Chaturvedi S**, Yu J, Brown J, Wei A, Selvakumar S, Gerber GF, Moliterno AR, Streiff MB, Kraus

P, Logue CM, Yui JC, Naik RP, Latif H, Lanzkron S, Braunstein EM, Brodsky RA, Gottesman RF, Lin DD. Silent cerebral infarction during immune TTP remission - prevalence, predictors and impact on cognition. Blood. 2023 May 22:blood.2023019663. doi: 10.1182/blood.2023019663. Online ahead of print.

41. Harris Z, Kaizer H, Karantanos T, Williams, DM, **Chaturvedi S**, Jain T, Resar LM, Moliterno AR, Braunstein EM. Characterization of myeloproliferative neoplasms in the pediatric and young adult population. British J Haematol 2023;201(3):449-458.
42. Lo BD, Pippa A, Sherd I, Scott AV, Thomas AJ, Hendricks EA, Ness PM, **Chaturvedi S**, Resar LMS, Frank SM. Clinical Outcomes, Blood Utilization, and Ethical Considerations for Pediatric Patients in a Bloodless Medicine and Surgery Program. Anesth Analg. 2024 Feb 1;138(2):465-474.
43. Abou-Ismail MY, Zhang C, Presson AP, **Chaturvedi S**, Antun AG, Farland A, Woods R, Metjian A, Park Y, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A Descriptive Analysis of Fatal Outcomes in Immune Thrombotic Thrombocytopenic Purpura in the USTMA TTP Registry. Blood Adv. 2023 Dec 15:bloodadvances.2023010807.
44. Bakow B, Yanek L, Crowther M, **Chaturvedi S**. Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation. Thromb Res 2024 [Epub ahead of print]
45. Abou-Ismail MY, Zhang C, Presson AP, **Chaturvedi S**, Antun AG, Farland A, Woods R, Metjian A, Park Y, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura. Res Pract Throm Haem 2024 [Epub ahead of print].
46. Brown J, Martin C, Mazepa M, **Chaturvedi S**. Consequences of unmet pregnancy-specific needs in women with immune TTP. Blood VTH 2024; 1(10):100003.
47. Cole MA, Ranjan N, Gerber GF, Pan XZ, Flores-Guerrero D, **Chaturvedi S**, Sperati CJ, McCrae KR, Brodsky RA. Complement biosensors identify a classical pathway stimulus in atypical hemolytic uremic syndrome. Blood. 2024 Dec 12;144(24):2528-2545.
48. Fatola A, Evans MD, Brown J, Davis E, Johnson A, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Eubanks S, Akwaa F, Clover T, Kreuziger LB, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Lim MY, Kocher NK, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Mazepa M, **Chaturvedi S**. Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era. Blood Adv. 2025 Jan 28;9(2):417-424.
49. Sullivan SD, **Chaturvedi S**, Gautam P, Arnaud A. Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States. J Manag Care Spec Pharm. 2024 Dec 23:1-12.
50. Mahmoud AA, Mostafa M, Abdelhay A, Abou-Ismail MY, **Chaturvedi S**. Characterization of bleeding in thrombotic thrombocytopenic purpura in the pre caplacizumab era: a retrospective nationwide analysis. Res Pract Thromb Haemost. 2024 Dec 12;9(1):102654.
51. Ahmad SA, Liu O, Feng A, Kalra A, Dev A, Spann M, Gusdon AM, **Chaturvedi S**, Cho SM. Prevalence and Characteristics of Acute Ischemic Stroke and Intracranial Hemorrhage in patients with Immune Thrombocytopenia Purpura and Immune Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis. Neurol Res Pract. 2025 Mar 17;7(1):19.
52. Coppo P, Bubenheim M, Benhamou Y, Völker L, Brinkkötter P, Kühne L, Knöbl P, Mingot Castellano ME, Pascual-Izquierdo C, de la Rubia J, del Rio Garma J, **Chaturvedi S,** Masias C, Mazepa MA, Zheng XL, Sinkovits G, Réti M, Patriquin C, Pavenski K, Boechat T, Farias J, Oliveira Ribeiro EF, de Andrade MLL, Veyradier A, Joly B, Bouzid R, Sakai K, Matsumoto M, Mancini I, Agosti P, Peyvandi F, Gavriilaki E, Stubbs M, Hmaid A, Cataland S, Lämmle B, Scully M. Caplacizumab Added to Plasma Exchange and Immunosuppression Hastens Recovery and Improves Survival in Immune TTP: an International Real-World Study of the TTP-IWG (The Capla 1000+ Project). Lancet EClinicalMedicine. 2025 Mar 30;82:103168.

53. Lossos C, Brown J, Sheikhbahaei S, Hubben A, Liu SC, McCrae KR, **Chaturvedi S**, Naik RP, Francischetti IMB. Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy. Blood Vessel Thromb Hemost. 2024 Jun;1(2):100006. .
54. Ly A, Ahmad SA, Liu O, Feng SN, Kalra A, Dev A, Spann M, **Chaturvedi S**, Hong S, Cho SM. Acute stroke in children with immune thrombocytopenia: A systematic review and meta-analysis. Br J Haematol. 2025;206(5):1450-1457.
55. Gómez-Bañuelos E, Ida Celia A, Trejo-Zambrano MI, Robles-De Anda JA, Paz M, **Chaturvedi S**, Conti F, Alessandri C, Tiniakou E, Goldman DW, Brodsky RA, Petri M, Andrade F. TFAM antibodies link mitochondrial damage with anti-phospholipid syndrome and thrombosis in SLE. Annals of Rheumatic Diseases 2025;84(9)1501-1511.
56. Ranjan N, Cole MA, Gerber GF, Crowther MA, Braunstein EM, Flores-Guerrero D, Haddaway K, Reed A, Streiff MB, McCrae KR, Petri M, **Chaturvedi S**, Brodsky RA. Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2025 Aug 20:S0003-4967(25)04249-9. doi: 10.1016/j.ard.2025.07.016. Epub ahead of print. PMID: 40841298.
57. Barnett B, Patell R, Angelini D, Tefera L, Schaefer JK, Li A, Bernal AG, **Chaturvedi S**, Mahajan A, Lake L, May J, Parks AL. Patient-centered management of heavy menstrual bleeding while on anticoagulation: A survey study. Eur J Obstet Gynecol Reprod Biol. 2025;313:114650. PMID: 40816247.
58. Yu J, Brown J, Meade J, Gerber GF, Streiff MB, Kraus PS, Merrill SA, Pishko A, Yui JC, Naik RP, Brodsky RA, Lin DD, **Chaturvedi S**. Progressive Silent Cerebral Infarction is Associated with Stroke and Persistent Cognitive Impairment in iTTP Survivors. Blood Adv. 2025 Aug 12:bloodadvances.2025017274. doi: 10.1182/bloodadvances.2025017274. Epub ahead of print. PMID: 40795203.
59. Selvakumar S, Yu J, Meade, J, **Chaturvedi S**. Impact of Cognitive Impairment on Depression and Reduced Quality of Life Among Survivors of Thrombotic Thrombocytopenic Purpura. Hematol Rep 2025 (Accepted, in press).
60. Javed B, Brown J, Meade J, Nambi V, Li A, **Chaturvedi S**, Sukumar S. Standard Cardiovascular Risk Prediction Scores Underestimate Risk in Immune-Mediated Thrombotic Thrombocytopenic Purpura Survivors. Res Pract Thromb Hemost 2025 (Epub ahead of print). doi: 10.1016/j.rpth.2025.103005
61. Mahmoud AA, Eltaher B, Shah P, Antun A, Masias C, Sridharan M, **Chaturvedi S**. Fetal and maternal morbidity in pregnant patients with thrombotic thrombocytopenic purpura: A Nationwide analysis. Transfusion. 2025 Oct 7. doi: 10.1111/trf.18442. Epub ahead of print. PMID: 41058144.
62. Chan A, Chrysafi P, Angelini D, Schaefer JK, Li A, **Chaturvedi S**, Mahajan A, Leben T, May J, Lake L, Patell R, Bernal AG, Parks AL. An international survey of clinician recommendations for physical activity after venous thromboembolism. Thromb Res. 2025 Nov;255:109478. doi: 10.1016/j.thromres.2025.109478. Epub 2025 Sep 18. PMID: 41005025.
63. Hubben A, Brown J, Burke L, Woodward L, Martin C, McCrae KR, **Chaturvedi S**. The Patient Reported Outcomes Measurement Information System (PROMIS) perspective of adults with longstanding atypical hemolytic uremic syndrome. Res Pract Thromb Haemost 2025 (Accepted. In press)
64. Rizaldi AA, Streiff MB, Kilic A, **Chaturvedi S**. Characteristics and Outcomes of Thromboembolism Following Cardiac Transplant: A multi-institutional retrospective study. Res Pract Thromb Haemost 2025 (Accepted. In press)
65. Selvakumar S, Yu J, Meade J, Chaturvedi S. Association of Cognitive Impairment with Reduced Health-Related Quality of Life and Depression Among Survivors of Thrombotic Thrombocytopenic Purpura. Hematol Rep 2025 (Accepted. In press).
66. Javed B, Yu J, Brown B, Meade J, Gerber GF, Streiff MB, Kraus P, Merrill SA, Pishko AM, Yui J, Naik RP, Brodsky RA, Lin DD, Chaturvedi S. Risk factors for silent cerebral infarction in immune-mediated thrombotic thrombocytopenic purpura. British J Hematol 2025 (Accepted. In press)
67. Hanna RM, **Chaturvedi S**, Ong ML, Nag A, Song Rui, Huynh L, Burdeau JA, Dug MS, Wang Y. Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Kidney Int 2025 (Accepted. In Press)